The estimated Net Worth of Life Science Ventures, L.P.... is at least $253 millió dollars as of 24 November 2020. Life P owns over 375,000 units of Stoke Therapeutics stock worth over $252,963,650 and over the last 5 years Life sold STOK stock worth over $0.
Life has made over 4 trades of the Stoke Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Life bought 375,000 units of STOK stock worth $14,625,000 on 24 November 2020.
The largest trade Life's ever made was buying 1,388,889 units of Stoke Therapeutics stock on 21 June 2019 worth over $25,000,002. On average, Life trades about 513,148 units every 87 days since 2019. As of 24 November 2020 Life still owns at least 17,161,713 units of Stoke Therapeutics stock.
You can see the complete history of Life P stock trades at the bottom of the page.
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... és Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics executives and other stock owners filed with the SEC include: